• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2017 News Releases

Webcast ImageWebcast
Q2 2017 MIMEDX GROUP INC Earnings Conference Call (Live)
Jul 27, 2017 at 10:30 a.m. ET
Q2 2017 MIMEDX GROUP INC Earnings Conference Call
Thursday, July 27, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
Jul 13, 2017MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range
In the news release, MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range, issued 13-Jul-2017 by MiMedx Group, Inc. over PR Newswire, we are advised by the company that the second bullet under the "Second Quarter 2017 Revenue Highlights" section should read, "Q2 2017 Revenue grew 33% over Q2 2016 revenue" and the first sentence of the second full paragraph should read, in relevant part, "...a $19.1 million or 33% increase over 2016 second quarter revenue of $57.3 million."... 
Printer Friendly Version
Jul 05, 2017MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down
MARIETTA, Ga., July 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company's contract with AvKARE has expired as planned effective June 30, 2017. MiMedx and AvKARE began planning the wind-down of the contract in 2015, leading up to the final expirati... 
Printer Friendly Version
Jun 15, 2017Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In Orthopedics
dHACM Allografts Retain Growth Factors And Bioactive Proteins Shown To Regulate Activity Of Cell Types, Including Stem Cells, That Are Critical To Orthopedic Repair Of Injured And Diseased Tissue MARIETTA, Ga., June 15, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announce... 
Printer Friendly Version
Jun 13, 2017MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS Meeting
MARIETTA, Ga., June 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today the presentation of new clinical data at the American Society of Colon and Rectal Surgeons 2017 Annual Scientific and Tripartite Meeting ("2017 ASCRS Annual Scientific Meeting"), showing  tha... 
Printer Friendly Version
Jun 01, 2017MiMedx to Present at the Jefferies 2017 Global Healthcare Conference
MARIETTA, Ga., June 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will present at the Jefferies 2017 Global Healthcare Conference in New York, New York.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EV... 
Printer Friendly Version
May 18, 2017MiMedx To Attend The 14th Annual Craig-Hallum Institutional Investor Conference
MARIETTA, Ga., May 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it will attend the 14th Annual Craig-Hallum Institutional Investor Conference in Minneapolis, Minnesota.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher... 
Printer Friendly Version
May 01, 2017MiMedx Receives Innovative Technology Supplier of the Year Award from Vizient, Inc.
The largest member-Driven Health Care Performance Improvement Company recognizes MiMedx for its positive impact on patient care MARIETTA, Ga., May 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today it has received the Innovative Technology Supplier of the Year Award from Vizi... 
Printer Friendly Version
Apr 28, 2017MiMedx Announces Record Results For First Quarter Of 2017
Company records 36% revenue growth, 261% increase in Net Income and 51% increase in Adjusted Net Income* over Q1 2016 MARIETTA, Ga., April 28, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the quarter ended March 31, 2017. First Quarter 2017 Hig... 
Printer Friendly Version
Apr 24, 2017MiMedx to Present at the European Wound Management Association Annual Conference
The Dynamic Impact of Epifix® Dehydrated Human Amnion/Chorion Membrane Allografts to be Presented at the Symposium MARIETTA, Ga., April 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today Company's participation in the European Wound Management Association ("EWMA") 2017 Confe... 
Printer Friendly Version
Apr 18, 2017MiMedx To Present At 5th Annual Cell & Gene Therapy Investor Day
MARIETTA, Ga., April 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that Dr. Mark Landy, Vice President – Strategic Initiatives, will represent the Company at the 5th Annual Cell & Gene Therapy Investor Day in Boston, Massachusetts.  The presentation will be conducted "... 
Printer Friendly Version
Apr 13, 2017MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance
Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016 MARIETTA, Ga., April 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its revenue results for the first quarter of 2017. First Quarter 2017 Revenue Highlights Revenue grew 36% over Q1 2016 revenue ... 
Printer Friendly Version
Apr 05, 2017The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Conference
Poster Abstracts, Booth Education and Symposia Demonstrate Clinical and Cost Effective Results of MiMedx EpiFix®, AmnioFix®, EpiCord®, AmnioCord® and AmnioFill® Allografts in Healing Chronic and Acute Wounds MARIETTA, Ga., April 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sec... 
Printer Friendly Version
Mar 24, 2017MiMedx To Present At The 16th Annual Needham Healthcare Conference
MARIETTA, Ga., March 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sectors of healthcare, announced today  that it will present at the Needham Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher... 
Printer Friendly Version
Mar 19, 2017MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors
NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES & EXCHANGE COMMISSION MARIETTA, Ga., March 19, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine and biopharmaceutical company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for multiple sectors of healthcare, announced today its Board of Directors has appointed Luis A. Aguilar, former Commissione... 
Printer Friendly Version
Mar 08, 2017MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference
COMPANY ALSO TO EXHIBIT AT AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MEETING MARIETTA, Ga., March 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and other birth tissues, human skin and bone, and patent-protected processes and proprietary platforms to develop and market advanced products and therapies, announced today that it will present at Canaccord's 12th Annual Musculoskeletal Confer... 
Printer Friendly Version
Mar 02, 2017MiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical initiatives to shareholders
MARIETTA, Ga., March 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today it will be hosting a webcast on Thursday, March 9, 2017 beginning at 10:30 a.m. Eastern Time to discuss numerous strategi... 
Printer Friendly Version
Mar 01, 2017MiMedx Audit Committee Announces Completion Of Its Investigation
AUDIT COMMITTEE FINDS NO WRONGDOING BY MIMEDX MANAGEMENT MARIETTA, Ga., March 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue allografts and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that the Audit Committee of its Board of Directors has comple... 
Printer Friendly Version
Feb 23, 2017MiMedx Announces 2016 Record Results
MARIETTA, Ga., Feb. 23, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced its record results for the fourth quarter and full year ended December 31, 2016. Full Year 2016 Highlights are: Revenue is a ... 
Printer Friendly Version
Feb 16, 2017MiMedx Announces Release Date for 2016 Full Year Results
MARIETTA, Ga., Feb. 16, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2016, will be released before the opening of the market on Thursd... 
Printer Friendly Version
Feb 07, 2017Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery
ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthc... 
Printer Friendly Version
Feb 06, 2017MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the decision of its Board of Directors to authorize an increase in the Company's Share Repurchase Program. This action by the MiMe... 
Printer Friendly Version
Feb 03, 2017MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, commented today regarding the Food and Drug Administration's ("FDA's") recently published 2017 calendar year guidance agenda. The tissue-related Guida... 
Printer Friendly Version
Jan 24, 2017Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction
STUDY DEMONSTRATES THAT dHACM TREATMENT EFFECTS IMPROVED CELL SURVIVAL, ENHANCED VASCULARIZATION, AND RECRUITMENT OF AUTOLOGOUS STEM CELLS WITHIN INFARCTED CARDIAC TISSUE MARIETTA, Ga., Jan. 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Denta... 
Printer Friendly Version
Jan 09, 2017MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance
$246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015 MARIETTA, Ga., Jan. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced ... 
Printer Friendly Version
Jan 03, 2017MiMedx to Present at 35th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Jan. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the schedule for its presentation at the 35th Annual J.P. Morgan Healthcare Conference.  Parker H. "Pete" Petit, Chairman and CEO, Wil... 
Printer Friendly Version

Products

CONTACT US

888.543.1917